Dishman Carbogen Amcis Stock Screener | Share Price & Fundamental Analysis

DCAL Pharmaceuticals
Screen Dishman Carbogen Amcis share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹254.87
▲ 0.09 (0.04%)
2026-01-05 00:00:00
Share Price BSE
₹255.15
▲ 0.50 (0.20%)
2026-01-05 00:00:00
Market Cap ₹3,882.58 Cr.
P/B Ratio 0.60
EPS (TTM) ₹0.21
Dividend Yield -
Debt to Equity 0.41
52W High ₹314.00
52W Low ₹219.68
Operating Margin 20.00%
Profit Margin 5.94%
Revenue (TTM) ₹724.00
EBITDA ₹149.00
Net Income ₹43.00
Total Assets ₹9,999.00
Total Equity ₹5,832.00

Dishman Carbogen Amcis Share Price History - Stock Screener Chart

Screen DCAL historical share price movements with interactive charts. Analyze price trends and patterns.

Dishman Carbogen Amcis Company Profile - Fundamental Screener

Screen Dishman Carbogen Amcis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DCAL shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE385W01011

Dishman Carbogen Amcis Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen DCAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 9,999 9,581 9,454 8,638 8,366 8,200 7,329 7,177 6,593
Current Assets 2,200 1,928 1,918 1,839 1,704 1,779 1,554 1,546 1,245
Fixed Assets 7,055 6,724 6,188 5,773 5,698 5,678 5,098 5,066 4,852
Liabilities
Total Liabilities 9,999 9,581 9,454 8,638 8,366 8,200 7,329 7,177 6,593
Current Liabilities 2,243 1,399 1,845 1,669 1,377 916 751 891 786
Non-Current Liabilities 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 5,832 5,628 5,810 5,549 5,699 5,715 5,379 5,107 4,814
Share Capital 31 31 31 31 31 31 32 32 0
Reserves & Surplus 5,800 5,596 5,778 5,518 5,668 5,684 5,347 5,075 4,814
Screen DCAL income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec
Revenue 724 733 661 662 525 796 690 625 730 595 657 573 546 623 646
Expenses 575 570 504 595 500 645 542 613 602 529 610 559 452 535 529
EBITDA 149 163 157 67 25 151 148 13 128 66 47 14 94 88 118
Operating Profit % 20.00% 19.00% 23.00% 9.00% 4.00% 18.00% 21.00% 1.00% 17.00% 10.00% 6.00% 2.00% 16.00% 13.00% 17.00%
Depreciation 79 81 84 85 71 72 72 76 70 75 80 84 75 80 50
Interest 42 43 42 31 32 37 49 24 29 28 33 16 19 20 22
Profit Before Tax 28 39 31 -49 -78 42 27 -88 30 -36 -66 -85 0 -12 46
Tax -15 15 -35 21 0 9 22 -17 13 5 -7 -41 -4 -2 -1
Net Profit 43 23 65 -70 -78 33 5 -71 17 -41 -60 -45 4 -10 47
EPS 2.75 1.49 4.16 -4.46 -4.95 2.11 0.30 -4.51 1.08 -2.61 -3.80 -2.85 0.26 -0.64 3.00

Dishman Carbogen Amcis Cash Flow Screener - Liquidity Fundamentals

Screen DCAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2012-March
Operating Activities 375 379 266 355 513 585 282 226 303 154
Investing Activities -196 -225 -494 -619 -380 -442 -169 -297 -107 -104
Financing Activities -102 -22 250 130 -11 -98 -102 78 -137 -68
Net Cash Flow 77 132 22 -133 122 46 11 7 59 -19
Screen DCAL shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar
Promoter Holding 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
FII Holding 9.49% 9.93% 8.07% 8.70% 8.04% 8.17% 8.74% 0.00%
DII Holding 1.26% 1.27% 1.37% 2.37% 1.48% 1.23% 1.42% 2.56%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 25.31% 25.36% 26.84% 25.17% 27.10% 27.43% 26.22% 24.61%
Other Holding 4.62% 4.11% 4.39% 4.45% 4.06% 3.85% 4.29% 13.50%
Shareholder Count 50,757 49,744 49,455 50,656 53,683 55,280 52,822 56,583

Dishman Carbogen Amcis Dividend Screener - Share Yield Analysis

Screen DCAL dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.20 0.37%
2018-March ₹0.00 0.00%
2017-March ₹1.20 0.37%
2016-March ₹0.00 0.00%

Dishman Carbogen Amcis Index Membership - Market Screener Classification

Screen DCAL by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.

Dishman Carbogen Amcis Market Events Screener - Corporate Actions

Screen DCAL market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA -4.79%
Annual General Meeting NA 3.83%
2025-11-04 2025-11-04 Quarterly Result Announcement NA -0.44%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -0.81%
2025-05-21 2025-05-21 Quarterly Result Announcement NA 1.32%
2025-02-12 2025-02-12 Quarterly Result Announcement NA -5.97%
2024-11-13 2024-11-13 Quarterly Result Announcement NA -2.31%
2017-03-27 2017-03-27 Change Of Name NA -

Dishman Carbogen Amcis Competitors Screener - Peer Comparison

Screen DCAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,470 39.35 54,729 9.71% 10,980 39.06
Divis Laboratories 169,727 68.64 9,712 18.67% 2,191 44.96
Torrent Pharmaceuticals 129,188 60.42 11,539 6.99% 1,911 59.35
Cipla 121,028 22.17 28,410 7.12% 5,291 42.76
Dr Reddys Laboratories 105,706 18.42 33,741 16.73% 5,725 49.97
Lupin 95,718 21.87 22,910 13.74% 3,306 50.10
Zydus Life Science 91,547 18.03 23,511 18.55% 4,615 34.06
Mankind Pharma 89,868 50.11 12,744 20.90% 2,007 40.67
Aurobindo Pharma 68,866 20.16 32,346 9.43% 3,484 46.33
Alkem Laboratories 65,605 26.89 13,458 3.70% 2,216 37.45

Dishman Carbogen Amcis Company Announcements - News Screener

Screen DCAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-02 Board Meeting Outcome for BOARD MEETING OUTCOME FOR BOARD APPROVES ISSUE OF SENIOR SECURED RATED LISTED TRANSFERABLE TAXABLE REDEEMABLE NON-CONVERTIBLE DEBENTURES AGGREGATING UP TO RS. 50 CRORES View
2025-12-29 Closure of Trading Window View
2025-12-29 Board Meeting Intimation for Considering And Approving The Proposal Of Fund Raising By Way Of Issuance Of Non-Convertible Debentures By Way Of Private Placement Subject To Such Regulatory Or Statutory Approvals As May Be Required View
2025-12-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-12 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-11-11 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2025-11-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2025-11-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-11-05 Announcement under Regulation 30 (LODR)-Investor Presentation View
2025-11-04 Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2025. View
2025-11-04 Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2025. View
2025-10-31 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-10-30 Board Meeting Intimation for Considering Take On Record And Approving The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2025 View
2025-10-16 INTIMATION OF MERGER OF TWO MATERIAL WHOLLY-OWNED STEP-DOWN SUBSIDIARIES OF THE COMPANY View
2025-10-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2025-10-07 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM View
2025-09-29 Announcement under Regulation 30 (LODR)-Change in Management View
2025-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM View
2025-09-29 Shareholder Meeting / Postal Ballot-Scrutinizers Report View